(Charlottesville, VA, April 26, 2007) – PluroGen Therapeutics, Inc. today announced an R&D agreement between the companies whereby DPT will become the preferred partner for CMC work and manufacturing scale-up of PluroGen Therapeutics’ PluroGel topical drug delivery technology and the PluroGen’s first topical antibiotic for 2nd and 3rd degree burns.

Commenting on this agreement, Neal G. Koller, President & CEO of PluroGen, said, “Signing of this agreement and commencement of CMC and manufacturing scale-up work meets one of our stated milestones for 2007. We believe that this relationship will provide PluroGen with an assured source of quality products for clinical evaluation and commercialization and will encourage our future partners, investors and customers to view Plurogen as a company that can offer research, development, manufacturing and high quality topical drug products. DPT was chosen based on their proven capability in topical drug products, our positive experience in working with them and a shared belief in the value of opportunities for PluroGen’s technology platform materials.”

Paul Josephs, Vice President of Sales and Commercial Operations for DPT, commented, “PluroGen is clearly on the leading edge of topical drug delivery technologies and products. As a leading supplier of gel products to the market, DPT looks to these kinds of relationships to enable us to assure continuity in the value chain from development to production. We look forward to developing further business relationships of this kind.”


About PluroGen Therapeutics, Inc.
Headquartered in Charlottesville, Va., PluroGen. is a biopharmaceutical company commercializing its patent-protected technology platform of topical drug delivery materials, drug efficacy enhancement materials and novel therapeutics into protected, advanced therapeutic products for simple and complex wound healing. The product portfolio targets improved, protected therapies for the 6 Areas of Therapeutic Treatment (ATT) of tissue healing (cleansing, infection, pain, inflammation, tissue salvage, tissue regeneration).

The company’s first two products, PluroGel Silver Sulfadiazine and TAG, are based on an advanced patent protected topical drug delivery technology that has been successfully used in the U.Va. Medical Center on more than 2,000 patients (approved through the UVA Medical Center’s internal pharmacy approval process). PluroGen’s management and board of directors individually have more than 20 years of experience working closely with the burn and wound care communities and the life science industry.


About DPT

DPT, with a heritage dating back to 1938, is an independent, privately owned company that strives to build long-term partnerships. From development to manufacturing, packaging and distribution of semi-solid, liquid, Rx, OTC, and biotech products, our experience gives our customers confidence in outsourcing Advanced Development Solutions, Specialized Production Solutions, and Innovative Packaging Solutions. Combined with DPT’s excellent regulatory compliance history, we get you to market with a quality product every time. For more information, visit DPT’s website at www.dptlabs.com.


Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that forward-looking statements are subject to certain risks and uncertainties, which could cause actual results to differ materially and which are identified from time to time in the Company’s reports filed with the U.S. Securities and Exchange Commission. PluroGen Therapeutics, Inc. claims the
protection of the Safe Harbor for forward-looking statements contained in the Private Securities Litigation
Reform Act of 1995.

For more information about PluroGen Therapeutics, Inc., visit the Company’s web site at www.plurogen.
com

Information included on PluroGen Therapeutics, Inc website is not incorporated herein by reference or
otherwise.